Annals of Oncology Advance Access originally published online on September 4, 2007
Annals of Oncology 2007 18(12):2020-2024; doi:10.1093/annonc/mdm375
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
hematologic malignancies |
Pathology and clinical course of MALT lymphoma with plasmacytic differentiation
1 Department of Internal Medicine I, Medical University of Vienna, Austria
2 Department of Pathology, Medical University of Vienna, Austria
3 Department of Nuclear Medicine, Medical University of Vienna, Austria
* Correspondence to: M. Raderer, MD, Department of Internal Medicine I, Division of Oncology, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Tel/Fax: +43-1-40400-2296; E-mail: markus.raderer{at}meduniwien.ac.at
Background: The feature of plasmacytic differentiation (PCD) is present in up to 30% of patients diagnosed with mucosa-associated lymphoid tissue (MALT) lymphoma. To date, the influence of PCD on the clinical course of MALT lymphoma has not been assessed.
Patients and methods: Therefore, we have retrospectively analysed the clinical characteristics and the course of the disease in 34 (25%) patients with PCD as compared with 101 (75%) MALT lymphoma patients without this histological feature.
Results: Patients with PCD had significantly more extragastric lymphomas [28 of 34 (82%) versus 54 of 101 (53%), P = 0.003] and a significantly lower rate of t(11;18) [2 of 26 (8%) versus 22 of 72 (31%), P = 0.02]. There was no significant difference of age at diagnosis (62 versus 64 years, P = 0.64), relapse rate (48% versus 37%, P = 0.27), estimated median time to progression (43 versus 65 months, P = 0.14), monoclonal gammopathy (50% versus 44%, P = 0.63), t(14;18) involving IGH/MALT1 (11% versus 8%, P = 0.68), trisomy 3 (31% versus 27%, P = 0.69), trisomy 18 (8% versus 10%, P = 0.74) and the presence of autoimmune diseases between both groups (53% versus 37%, P = 0.09).
Conclusion: In conclusion, we found that PCD is predominantly found in extragastric MALT lymphoma but has no significant impact on clinical course and prognosis.
Key words: clinical course, MALT lymphoma, pathology, plasmacytic differentiation
Received for publication March 28, 2007. Revision received June 18, 2007. Accepted for publication June 27, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Troch, C. Zielinski, and M. Raderer Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) Ann. Onc., August 1, 2009; 20(8): 1446 - 1447. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Troch, C. Jonak, L. Mullauer, A. Puspok, M. Formanek, W. Hauff, C. C. Zielinski, A. Chott, and M. Raderer A phase II study of bortezomib in patients with MALT lymphoma Haematologica, May 1, 2009; 94(5): 738 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stasi, M. L. Evangelista, M. Brunetti, S. Bussa, R. Maritati, A. Gallo, L. Turrini, S. Taccogna, A. Crescenzi, and F. Angelini Primary Gastric Plasmacytoma and Helicobacter pylori Infection J. Clin. Oncol., January 1, 2009; 27(1): 150 - 153. [Full Text] [PDF]
|
|